Ribena, Nutrition Labelling and the Trade Practice Act

On 23 March 2006, GlaxoSmithKline Australia contacted the Australian Competition and Consumer Commission (‘ACCC’) to inform the ACCC of concerns over some of their own Ribena branded products. These concerns related to Vitamin C content claims and references to Vitamin C levels in blackcurrants compared to oranges. Consequently, GlaxoSmithKline provided the ACCC with undertakings intended to address these concerns. In this article we examine what occurred, the undertakings given and what food and beverage manufacturers can learn from GlaxoSmithKline’s experience.

This article is available to Subscribers only!

Not yet a Subscriber? Become a Member of FoodLegal